Agilon Health's Q4 2024: Contradictions in Part D Management, Membership Repricing, and Cost Trends

Generated by AI AgentAinvest Earnings Call Digest
Wednesday, Feb 26, 2025 9:37 am ET1min read
AGL--
These are the key contradictions discussed in Agilon Health's latest 2024Q4 earnings call, specifically including: Part D risk management, membership repricing, CMS cost trend expectations, and contract renegotiations:



Membership and Revenue Growth:
- Agilon Health saw a 36% increase in Medicare Advantage (MA) membership to 527,000 members year-over-year in Q4 2024.
- Total revenue grew 44% in Q4 to $1.52 billion and 40% year-over-year to $6.06 billion.
- Growth was primarily driven by the expansion of the 2024 partner class and organic growth in existing classes.

Medical Margin and Cost Trends:
- Medical margin for Q4 was $1 million, with a full-year margin of $205 million, impacted by higher Medicare Part D costs and unfavorable prior year development.
- The company recorded a gross medical cost trend of 6.8% for 2024, with plans for 5.3% net trend in 2025 due to payor bid adjustments and cost sharing reduction.

Strategic Actions and Cost Management:
- Agilon reduced Medicare Part-D exposure to less than 30% of its membership for 2025, focusing on managed growth and measured expansion.
- The company exited 2 unprofitable partnerships and introduced tighter attribution management, enhancing cost discipline and risk reduction strategies.

Quality and Clinical Programs:
- Agilon's managed care programs achieved 130 million in gross savings, beating the national cost trend by approximately 280 basis points.
- The company emphasized its ability to manage cost trends relative to benchmarks and deliver top-tier quality performance, reflected in readings, hospital admissions, and ER visits rates 20-30% better than the local fee-for-service benchmark.

Discover what executives don't want to reveal in conference calls

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet